FDA Approves HRT Label Changes - Takeaways - MDSpire

FDA Approves HRT Label Changes

The agency cited updated evidence in revising hormone therapy safety language.

  • By

  • Kathryn Wighton

  • February 12, 2026

  • 2 min

Share

  • 1

    The FDA has approved labeling changes for six menopausal hormone therapy products, removing specific risk statements from the boxed warning.

  • 2

    The updated labeling reflects a comprehensive review of scientific literature regarding menopausal hormone therapies.

  • 3

    Approved products include systemic combination therapy, systemic estrogen-alone therapy, and topical vaginal estrogen therapy.

  • 4

    Hormone therapy can significantly improve quality of life by alleviating symptoms like hot flashes and preventing bone loss.

  • 5

    Despite potential benefits, hormone therapy usage remains low, with only about 2 million women receiving prescriptions in 2020.

Original Source(s)

FDA Approves HRT Label Changes

  • by Kathryn Wighton

  • February 12, 2026

Related Content

Divergence in Menopause Symptom Narratives Between Online and Clinical Settings

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

Menstrual Fluid May Aid in Endometriosis Detection

Single-nucleus sequencing of menstrual fluid identified epithelial gene signatures and prioritized five candidate biomarkers that warrant validation in larger studies.